Samuel Bates Martin - May 30, 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP AND CFO
Signature
/s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin
Stock symbol
CLDX
Transactions as of
May 30, 2024
Transactions value $
-$932,275
Form type
4
Date filed
6/3/2024, 04:05 PM
Previous filing
Jan 4, 2024
Next filing
Jun 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $260K +25K +71.17% $10.38 60.1K May 30, 2024 Direct
transaction CLDX Common Stock Sale -$1.19M -35K -58.21% $34.05 25.1K May 30, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -25K -23.67% $0.00 80.6K May 30, 2024 Common Stock 25K $10.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.